Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major

Vaccine

Volumn 24, Issue 14, 2006, Pages 2521-2529

  Chenik, M ^a   Louzir, H ^a   Ksontini, H ^a   Dilou, A ^a   Abdmouleh, I ^a   Dellagi, K ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

Histone H2B; Leishmania; Vaccine candidate

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; HISTONE H2B; LEISHMANIA VACCINE; PROTOZOAL PROTEIN; RECOMBINANT HISTONE H2B PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; HUMORAL IMMUNITY; INFECTION SENSITIVITY; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE VIRULENCE; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROVOCATION TEST; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIGENS, PROTOZOAN; HISTONES; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; VACCINATION;

EID: 33344465265     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.12.027     Document Type: Article

References (30)

1. P. Desjeux Leishmaniasis. Public health aspects and control Clin Dermatol 14 5 1996 417 423
2. WHO. E, Commitee. Control of the leishmaniasis. WHO Tech Rep Ser; 1990
3. J. Alexander, and D.G. Russell The interaction of Leishmania species with macrophages Adv Parasitol 31 1992 175 254
4. E. Handman Cell biology of Leishmania Adv Parasitol 44 1999 1 39
5. S.Y. Guirges Natural and experimental re-infection of man with Oriental sore Ann Trop Med Parasitol 65 2 1971 197 205
6. C.R. Davies, E.A. Llanos-Cuentas, S.D. Pyke, and C. Dye Cutaneous leishmaniasis in the Peruvian andes: an epidemiological study of infection and immunity Epidemiol Infect 114 2 1995 297 318
7. Ben Salah A, Louzir H, Chlif S, Mokni M, Zaatour A, Raouene M, et al. The predictive validity of naturally acquired delayed-type hypersensitivity to leishmanin in resistance to Leishmania major-associated cutaneous leishmaniasis. J Infect Dis 2005;192(11):1981-7.
8. I. Sharifi, A.R. FeKri, M.R. Aflatonian, A. Khamesipour, A. Nadim, and M.R. Mousavi Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran Lancet 351 9115 1998 1540 1543
9. E.A. Khalil, A.M. El Hassan, E.E. Zijlstra, M.M. Mukhtar, H.W. Ghalib, and B. Musa Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan Lancet 356 9241 2000 1565 1569
10. R.X. Armijos, M.M. Weigel, M. Calvopina, A. Hidalgo, W. Cevallos, and J. Correa Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis Vaccine 22 9-10 2004 1320 1326
11. I.D. Velez, K. Gilchrist, M.P. Arbelaez, C.A. Rojas, J.A. Puerta, and C.M. Antunes Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia Trans R Soc Trop Med Hyg 99 8 2005 593 598
12. J. Kubar, and K. Fragaki Recombinant DNA-derived leishmania proteins: from the laboratory to the field Lancet Infect Dis 5 2 2005 107 114
13. R.N. Coler, and S.G. Reed Second-generation vaccines against leishmaniasis Trends Parasitol 21 5 2005 244 249
14. A. Sjolander, T.M. Baldwin, J.M. Curtis, and E. Handman Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis J Immunol 160 8 1998 3949 3957
15. P.C. Melby, F.A. Neva, and D.L. Sacks Profile of human T cell response to leishmanial antigens. Analysis by immunoblotting J Clin Invest 83 6 1989 1868 1875
16. P.C. Melby, and D.L. Sacks Identification of antigens recognized by T cells in human leishmaniasis: analysis of T-cell clones by immunoblotting Infect Immun 57 10 1989 2971 2976
17. P.C. Melby, G.B. Ogden, H.A. Flores, W. Zhao, C. Geldmacher, and N.M. Biediger Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library Infect Immun 68 10 2000 5595 5602
18. P. Probst, E. Stromberg, H.W. Ghalib, M. Mozel, R. Badaro, and S.G. Reed Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning J Immunol 166 1 2001 498 505
19. S. Iborra, M. Soto, J. Carrion, C. Alonso, and J.M. Requena Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniasis Vaccine 22 29-30 2004 3865 3876
20. Saldarriaga OA, Travi BL, Park W, Perez LE, Melby PC. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine 2005 (in press).
21. H. Louzir, P.C. Melby, A. Ben Salah, H. Marrakchi, K. Aoun, and R. Ben Ismail Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major J Infect Dis 177 6 1998 1687 1695
22. C. Kebaier, H. Louzir, M. Chenik, A. Ben Salah, and K. Dellagi Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response Infect Immun 69 8 2001 4906 4915
23. P. Scott, E. Pearce, P. Natovitz, and A. Sher Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes J Immunol 139 1 1987 221 227
24. A.M. Mora, W. Mayrink, R.T. Costa, C.A. Costa, O. Genaro, and E. Nascimento Protection of C57BL/10 mice by vaccination with association of purified proteins from Leishmania (Leishmania) amazonensis Rev Inst Med Trop Sao Paulo 41 4 1999 243 248
25. Y. Ben Achour, M. Chenik, H. Louzir, and K. Dellagi Identification of a disulfide isomerase protein of Leishmania major as a putative virulence factor Infect Immun 70 7 2002 3576 3585
26. T. Laskay, A. Diefenbach, M. Rollinghoff, and W. Solbach Early parasite containment is decisive for resistance to Leishmania major infection Eur J Immunol 25 8 1995 2220 2227
27. A.P. Wolffe, and J.J. Hayes Chromatin disruption and modification Nucleic Acids Res 27 3 1999 711 720
28. M. Soto, J.M. Requena, L. Quijada, M.J. Perez, C.G. Nieto, and F. Guzman Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis Clin Exp Immunol 115 2 1999 342 349
29. I.A. Maalej, M. Chenik, H. Louzir, A. Ben Salah, C. Bahloul, and F. Amri Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis Am J Trop Med Hyg 68 3 2003 312 320
30. S. Sakaguchi Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self Nat Immunol 6 4 2005 345 352